×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
26678033
2016
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma.
24710085
2015
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
25656898
2015
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
25370471
2015
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
24918823
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
24576830
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
24586605
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
25157968
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Prognostic value of BRAF mutations in localized cutaneous melanoma.
24388723
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
24583796
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
24508103
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
24508103
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
25157968
2014
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
23273605
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
23524406
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
23237741
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
23248257
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
23614898
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
22972589
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
23833300
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
23248257
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
23715574
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
23918947
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
23918947
2013
×
Entrez Id:
673
Gene Symbol:
BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
23317446
2013